In 56 older and/or frail patients with stage III NSCLC unfit for concurrent chemoradiotherapy, sequential chemo-immunotherapy plus standard vs reduced thoracic radiotherapy gave estimated 1-year PFS of 84.3% vs 70.7%; non-comparative phase II, not powered for comparison.
RCTn = 56
Qi et al. Sequential chemo-immunotherapy followed by standard versus reduced thoracic radiotherapy for older and/or frail stage III non-small-cell lung cancer: A randomized open-label cohort trial